drugset

drugset / Trial / NCT00038233

Thalidomide for Multiple Myeloma

NCT00038233 ↗

Phase 3 Completed 27 enrolled M.D. Anderson Cancer Center Celgene Corporation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this protocol is to assess therapeutic activity of thalidomide in previously untreated patients with asymptomatic multiple myeloma.

Timeline

Start: 1999-05
Primary completion: 2005-04
Completion: 2005-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thalidomide	Other / unclassified	800 mg	Oral

Indications